Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment
Status:
COMPLETED
Trial end date:
2025-01-13
Target enrollment:
Participant gender:
Summary
Participants were enrolled and randomly divided in two groups. In group A, participants were prescribed Dapagliflozin 10 mg daily. In group B, participants were prescribed Empagliflozin 10 mg daily. All participants were followed-up in OPD after 12 weeks for assessment of ejection fraction.